Cargando…
Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma
Galactose-modified selenium nanoparticles (GA-SeNPs) loading with doxorubicin (DOX) for hepatocellular carcinoma (HCC) therapy was investigated in this paper. Selenium nanoparticles (SeNPs) were modified with galactose as tumor targeting moiety to fabricate tumor-targeted delivery carrier GA-SeNPs,...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327939/ https://www.ncbi.nlm.nih.gov/pubmed/31928356 http://dx.doi.org/10.1080/10717544.2018.1556359 |
_version_ | 1783386572555550720 |
---|---|
author | Xia, Yu Zhong, Jiayu Zhao, Mingqi Tang, Ying Han, Ning Hua, Liang Xu, Tiantian Wang, Changbing Zhu, Bing |
author_facet | Xia, Yu Zhong, Jiayu Zhao, Mingqi Tang, Ying Han, Ning Hua, Liang Xu, Tiantian Wang, Changbing Zhu, Bing |
author_sort | Xia, Yu |
collection | PubMed |
description | Galactose-modified selenium nanoparticles (GA-SeNPs) loading with doxorubicin (DOX) for hepatocellular carcinoma (HCC) therapy was investigated in this paper. Selenium nanoparticles (SeNPs) were modified with galactose as tumor targeting moiety to fabricate tumor-targeted delivery carrier GA-SeNPs, then doxorubicin was loaded onto the surface of GA-SeNPs for improving antitumor efficacy of DOX in HCC therapy. Chemical structure characterization of GA-Se@DOX showed that DOX was successfully loaded to the surface of GA-SeNPs to prepare functionalized antitumor drug delivery system GA-Se@DOX. GA-Se@DOX exhibited effective cellular uptake in HepG2 cells and entered HepG2 cells mainly by clathrin-mediated endocytosis pathway. GA-Se@DOX showed significant activity to induce the apoptosis of HepG2 cells in vitro. The western blotting result indicated that GA-Se@DOX induced HepG2 cells apoptosis via activating caspase signaling and Bcl-2 family proteins. Moreover, active targeting delivery system GA-Se@DOX exhibited excellent antitumor efficacy in vivo in comparison with passive targeting delivery system Se@DOX. Histology analysis showed that GA-Se@DOX exhibited no obvious damage to major organs including heart, liver, spleen, lung, and kidney under the experimental condition. Taken together, GA-Se@DOX may be one novel promising nanoscale drug candidate for HCC therapy. |
format | Online Article Text |
id | pubmed-6327939 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-63279392019-01-16 Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma Xia, Yu Zhong, Jiayu Zhao, Mingqi Tang, Ying Han, Ning Hua, Liang Xu, Tiantian Wang, Changbing Zhu, Bing Drug Deliv Research Article Galactose-modified selenium nanoparticles (GA-SeNPs) loading with doxorubicin (DOX) for hepatocellular carcinoma (HCC) therapy was investigated in this paper. Selenium nanoparticles (SeNPs) were modified with galactose as tumor targeting moiety to fabricate tumor-targeted delivery carrier GA-SeNPs, then doxorubicin was loaded onto the surface of GA-SeNPs for improving antitumor efficacy of DOX in HCC therapy. Chemical structure characterization of GA-Se@DOX showed that DOX was successfully loaded to the surface of GA-SeNPs to prepare functionalized antitumor drug delivery system GA-Se@DOX. GA-Se@DOX exhibited effective cellular uptake in HepG2 cells and entered HepG2 cells mainly by clathrin-mediated endocytosis pathway. GA-Se@DOX showed significant activity to induce the apoptosis of HepG2 cells in vitro. The western blotting result indicated that GA-Se@DOX induced HepG2 cells apoptosis via activating caspase signaling and Bcl-2 family proteins. Moreover, active targeting delivery system GA-Se@DOX exhibited excellent antitumor efficacy in vivo in comparison with passive targeting delivery system Se@DOX. Histology analysis showed that GA-Se@DOX exhibited no obvious damage to major organs including heart, liver, spleen, lung, and kidney under the experimental condition. Taken together, GA-Se@DOX may be one novel promising nanoscale drug candidate for HCC therapy. Taylor & Francis 2019-01-02 /pmc/articles/PMC6327939/ /pubmed/31928356 http://dx.doi.org/10.1080/10717544.2018.1556359 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Xia, Yu Zhong, Jiayu Zhao, Mingqi Tang, Ying Han, Ning Hua, Liang Xu, Tiantian Wang, Changbing Zhu, Bing Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma |
title | Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma |
title_full | Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma |
title_fullStr | Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma |
title_full_unstemmed | Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma |
title_short | Galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma |
title_sort | galactose-modified selenium nanoparticles for targeted delivery of doxorubicin to hepatocellular carcinoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6327939/ https://www.ncbi.nlm.nih.gov/pubmed/31928356 http://dx.doi.org/10.1080/10717544.2018.1556359 |
work_keys_str_mv | AT xiayu galactosemodifiedseleniumnanoparticlesfortargeteddeliveryofdoxorubicintohepatocellularcarcinoma AT zhongjiayu galactosemodifiedseleniumnanoparticlesfortargeteddeliveryofdoxorubicintohepatocellularcarcinoma AT zhaomingqi galactosemodifiedseleniumnanoparticlesfortargeteddeliveryofdoxorubicintohepatocellularcarcinoma AT tangying galactosemodifiedseleniumnanoparticlesfortargeteddeliveryofdoxorubicintohepatocellularcarcinoma AT hanning galactosemodifiedseleniumnanoparticlesfortargeteddeliveryofdoxorubicintohepatocellularcarcinoma AT hualiang galactosemodifiedseleniumnanoparticlesfortargeteddeliveryofdoxorubicintohepatocellularcarcinoma AT xutiantian galactosemodifiedseleniumnanoparticlesfortargeteddeliveryofdoxorubicintohepatocellularcarcinoma AT wangchangbing galactosemodifiedseleniumnanoparticlesfortargeteddeliveryofdoxorubicintohepatocellularcarcinoma AT zhubing galactosemodifiedseleniumnanoparticlesfortargeteddeliveryofdoxorubicintohepatocellularcarcinoma |